Reuters NEXT
Interview with Grab CEO & Co-Founder Anthony Tan
Sign up to watch live
September 15, 202111:47 AM PDTLast Updated 3 months ago
Healthcare & Pharmaceuticals
FDA staff say Pfizer COVID-19 boosters may not be needed, but do improve immunity
By Michael Erman

3 minute read
A vial labelled with the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine is seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/Illustration
Sept 15 (Reuters) - U.S. Food and Drug Administration scientists said on Wednesday that booster doses of Pfizer's (PFE.N) COVID-19 vaccine may not be needed, even though the third shot generates a higher immune response in recipients.
The FDA staff members said in a document prepared for outside advisors that it is still unproven that the efficacy of Comirnaty - the COVID-19 vaccine Pfizer developed with Germany's BioNTech SE - is declining.
"Some observational studies have suggested declining efficacy of Comirnaty over time against symptomatic infection or against the Delta variant, while others have not," they said in the document.
Register now for FREE unlimited access to reuters.com
"However, overall, data indicate that currently U.S.-licensed or authorized COVID-19 vaccines still afford protection against severe COVID-19 disease and death in the United States."
The FDA staff did say the booster dose met pre-specified conditions the regulator had set to show that the shot was generating an immune response.
However, they said in the document that licensure for the boosters should also consider ability to prevent hospitalization and death, as well as the dynamics of the pandemic in the United States.
The agency released the document on Wednesday for consideration by a committee of outside experts who will meet on Friday to decided whether to recommend if U.S regulators should approve the extra round of shots.
The FDA staff view reflects that of many scientists who have questioned whether the boosters are necessary broadly, even as President Joe Biden has pushed for the additional shots in the face of surging hospitalizations and deaths caused by the highly contagious Delta variant of the coronavirus.
loading
Biden set a Sept. 20 target to begin administering 100 million booster shots in the United States.
After the FDA meets, a panel of advisors to the U.S. Centers for Disease Control and Prevention is planning to meet next week to make its recommendation, according to White House Press Secretary Jen Psaki.
PFIZER ARGUES BOOSTER APPROVAL
Pfizer, in a document it prepared for the meeting, argued that U.S. regulators should approve a booster shot of its vaccine for use six months after the second dose due to waning effectiveness over time.
Pfizer said data from its own clinical trials showed that the vaccine's efficacy diminished by around 6% every two months after the second dose. It also said the incidence of breakthrough COVID-19 cases in that trial was higher among people who received their shots earlier.
The company also pointed to real world data from Israel and the United States showing declining effectiveness of the Pfizer/BioNTech vaccine.
The U.S drugmaker said in a roughly 300-participant clinical trial, the third dose generated a better immune response than the second. It also pointed to data from the booster program recently started in Israel to show that a third dose restores high levels of protection from the virus.
Earlier this week, two top FDA vaccine scientists were among the authors of an article saying they do not believe the current data supports giving the shots. One of those scientists - Marion Gruber, director of the FDA's Office of Vaccines Research and Review - will be speaking at Friday's meeting.
Some U.S. officials are hoping boosters might prevent mild cases and reduce transmission of the virus as well as reducing COVID-19 hospitalizations and deaths, which could hasten America's recovery.
Some countries have already begun COVID-19 booster campaigns. The United States authorized extra shots for people with vulnerable immune systems last month.
Register now for FREE unlimited access to reuters.com
Reporting by Michael Erman, Additional reporting from Manojna Maddipatla in Bengaluru; Editing by Nick Zieminski, Chizu Nomiyama and Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.
More from Reuters
Play video on original page

Europe telcos: tech giants should fund 5G rollout
Macau casino shares plunge after execs arrested
Evergrande shares dive after chairman sells stake
Nissan unveils $18 bln electrification push
Jack Dorsey steps down as Twitter CEO
Ignore '100 percent' of Friday's Omicron reaction -investor
The consumer is fine despite Black Friday sales -investor
U.S. orders redo of Amazon union vote in Alabama
CEO arrest sends Macau gambling group shares down
World stocks dive as virus variant spooks markets

Sign up for our newsletter
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Latest
Home
Media
Videos
Pictures
Graphics
Browse
World
Business
Legal
Markets
Breakingviews
Technology
Investigations
Lifestyle
About Reuters
About Reuters
Careers
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Newsletters
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Westlaw
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
Onesource
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
Checkpoint
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Refinitiv Workspace
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Refinitiv Data Catalogue
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Refinitiv World-Check
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Cookies
Terms of Use
Privacy
Corrections
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved